Clinical trials
Lung Cancer (NSCLC) clinical trials
Below are recruiting lung cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 1,079 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07754812RecruitingPhase 4
Oral paclitaxel with immunotherapy and SBRT before surgery for older adults with lung cancer
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 70 years+ - NCT07742332RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutant lung cancer
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07743021Recruiting
Blood sample study for better health screening
This study collects blood samples and health information over time to improve early detection of diseases. It may help researchers find ways to prevent serious conditions.
BalatonfüredAges 40 years+ - NCT07738367Enrolling by invitationPhase 2
Bronchial artery chemoembolization with drug therapy for advanced lung cancer
This trial tests a treatment called bronchial artery chemoembolization (BACE) combined with drug therapy for advanced non-small cell lung cancer. BACE delivers chemotherapy directly to the tumor through the blood vessel that feeds it, which may help control the cancer when standard treatments have stopped working.
Fuzhou, FujianAges 18–75 - NCT07738172RecruitingPhase 3
Osimertinib with or without lung tumor surgery for EGFR-mutated non-small cell lung cancer
This study tests whether adding surgery to remove the main lung tumor improves outcomes for people with stage 4 lung cancer that has a specific EGFR mutation and only limited spread. If you qualify, you will take the targeted drug osimertinib for 12 weeks, and if the tumor responds, you may be randomly assigned to either continue the drug alone or have the main tumor surgically removed and then continue the drug.
Taipei, Taipei CityAges 18 years+ - NCT07718672RecruitingPhase 2
New radiation technique for early-stage lung cancer
This trial compares a newer, more targeted type of radiation (hotspot SABR) with the standard SABR approach for people with early-stage non-small cell lung cancer. The goal is to see if the newer method works just as well or better while possibly reducing side effects.
Buffalo, New YorkAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06667154RecruitingPhase 2
Low-dose nivolumab plus chemo for early lung cancer
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
São José do Rio Preto, São PauloAges 18 years+ - NCT05435248RecruitingPhase 1/Phase 2
Study drug for advanced lung cancer with a specific EGFR change
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
Guangzhou, GuangdongAges 18 years+ - NCT07669779RecruitingPhase 2
Study of AK146D1 and AK112 for advanced lung cancer
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07660055RecruitingPhase 1
Radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (called 177Lu-DWJ155) that targets and kills cancer cells, along with a similar imaging agent (68Ga-DWJ155) used to see where the drug goes in the body. It is for people with certain advanced solid tumors that have not responded to standard therapies.
Omaha, NebraskaAges 18 years+ - NCT07661966Recruiting
Bright light therapy for melanoma or lung cancer patients starting immunotherapy
This study tests if daily bright light therapy can help people with advanced melanoma or lung cancer feel better during their first immunotherapy treatment. The light box is used at home for a short time each morning.
New York, New YorkAges 18 years+ - NCT07649629Recruiting
Blood test to help diagnose advanced lung cancer
This study tests whether a blood test (liquid biopsy) can help doctors better understand your lung cancer and plan your treatment. You'll have a blood sample taken alongside standard biopsies to see if the blood test provides useful information about your cancer.
Roma, RMAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Odense CAges 18 years+ - NCT07633626Recruiting
Vortioxetine for thinking problems from ALK lung cancer treatment
This trial tests whether a medication called vortioxetine can help improve memory, focus, and thinking problems caused by lorlatinib, a drug used to treat ALK-positive lung cancer. You would take vortioxetine alongside your current cancer treatment to see if it helps your brain function.
BogotáAges 18 years+ - NCT07637474Recruiting
Immune System and Lung Cancer Response to Immunotherapy
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
Rome, RomeAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT07637448RecruitingPhase 2
EGFR-targeted therapy plus immunotherapy for advanced lung cancer
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18 years+ - NCT07630168RecruitingPhase 2
Does infusion timing affect treatment response in solid tumors?
This trial tests whether the time of day you receive your infusion (morning vs. afternoon) affects how well your cancer treatment works. It is for people with advanced lung cancer or head and neck cancer that can be surgically removed.
Chapel Hill, North CarolinaAges 18 years+ - NCT07622186RecruitingPhase 2
SKB571 combination therapy for advanced lung cancer
This trial tests a new drug called SKB571, given in combination with other treatments, for non-small cell lung cancer (a common type of lung cancer). The study aims to see if this combination helps shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07613723RecruitingPhase 1
Testing ZI-MA4-1 immunotherapy for advanced solid cancers
This early-stage trial tests a new type of immunotherapy called ZI-MA4-1 in patients with advanced cancers (ovarian, lung, synovial sarcoma, or head and neck) that have stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells that have a specific protein called MAGE-A4.
LondonAges 18–75 - NCT07610798RecruitingPhase 1/Phase 2
Testing INV-8989 for Advanced Cancers With KRAS G12D Mutation
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07603856RecruitingPhase 2
Combining Immunotherapy and Radiation for Advanced Lung Cancer
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
Chicago, IllinoisAges 18 years+
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (nsclc)?
- Yes. Clin2 currently lists 1,079 recruiting lung cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.